Flagship Pioneering unveiled Expedition Medicines with a $50 million commitment to develop covalent‑binding small molecules using generative chemistry, quantum‑informed models and chemoproteomics. The new company out of Flagship’s incubator aims to tackle historically ‘undruggable’ targets and already disclosed a research collaboration with Pfizer on prostate cancer. Expedition’s launch underscores renewed venture capital and incubator appetite for AI‑first drug discovery platforms and marks another Flagship bet on integrating quantum chemistry and large‑scale experimental data.